Immunotherapy for Advanced HCC: Experts Answer Clinician Questions - a podcast by Clinical Care Options
from 2020-12-17T16:47:50
Link to CME: Claim Credit
In this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, answer clinician questions on current best practices and emerging applicationsĀ with immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma, with topics including:
- Optimal use of the newly approved immune checkpoint inhibitor/VEGF inhibitor combination of atezolizumab plus bevacizumab
- Use of immune checkpoint inhibitor therapy in patients with Child-Pugh B liver function
- Use of biomarkers to inform treatment for patients with advanced HCC
Presenters:
Amit G. Singal, MD, MS
Chief of Hepatology
Medical Director, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas
Lipika Goyal, MD
Lead of the Liver Cancer Research Program
Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Content based on an online CME program supported by an educational grant from Genentech, a member of the Roche Group.
Link to full program:
https://bit.ly/39V6s72
Further episodes of CCO Oncology Podcast
Further podcasts by Clinical Care Options
Website of Clinical Care Options